<b><font style="font-family: 'Times New Roman', Times">Inamed
    Acquisition</font></b><div style="margin-top: 6pt; font-size: 1pt"></div><div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On March23, 2006, the Company completed the acquisition of
    Inamed Corporation (Inamed), a global healthcare company that
    develops, manufactures, and markets a diverse line of products,
    including breast implants, a range of facial aesthetics and
    obesity intervention products.
</div><div style="margin-top: 6pt; font-size: 1pt"></div><div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Inamed acquisition was completed pursuant to an agreement
    and plan of merger, dated as of December20, 2005, and
    subsequently amended as of March11, 2006, by and among the
    Company, its wholly-owned subsidiary Banner Acquisition, Inc.,
    and Inamed, and an exchange offer made by Banner Acquisition to
    acquire Inamed shares for either $84.00 in cash or 0.8498 of a
    share of the Companys common stock, subject to proration
    so that 45% of the aggregate Inamed shares tendered were
    exchanged for cash and 55% of the aggregate Inamed shares
    tendered were exchanged for shares of the Companys common
    stock. In the exchange offer, the Company paid approximately
    $1.31billion in cash and issued 16,194,051shares of
    common stock through Banner Acquisition, acquiring approximately
    93.86% of Inameds outstanding common stock. Following the
    exchange offer, the remaining outstanding shares of Inamed
    common stock were acquired for approximately $81.7million
    in cash and 1,010,576shares of Allergan common stock
    through the merger of Banner Acquisition with and into Inamed in
    a merger in which Inamed survived as Allergans
    wholly-owned subsidiary. As a final step in the plan of
    reorganization, the Company merged Inamed into Inamed, LLC, a
    wholly-owned subsidiary of the Company. The consideration paid
    in the merger does not include shares of the Companys
    common stock and cash that were paid to former Inamed option
    holders for outstanding options to purchase shares of Inamed
    common stock, which were cancelled in the merger and converted
    into the right to receive an amount of cash equal to 45% of the
    in the money value of the option and a number of
    shares of the Companys common stock with a value equal to
    55% of the in the money value of the option.
    Subsequent to the merger, the Company issued 237,066shares
    of common stock and paid $17.9million in cash to satisfy
    its obligation to the option holders. The fair value of these
    shares of Company common stock and cash paid to option holders
    of Inamed common stock were included in the calculation of the
    purchase price detailed below.
</div><div style="margin-top: 6pt; font-size: 1pt"></div><div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table summarizes the components of the Inamed
    purchase price:
</div><div style="margin-top: 6pt; font-size: 1pt"></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF" width="100%">
<!-- Table Width Row -->
<tr style="font-size: 1pt" valign="bottom">
<td width="89%"></td> <!-- colindex=01 type=maindata -->
<td width="2%"></td> <!-- colindex=02 type=gutter -->
<td align="right" width="4%"></td> <!-- colindex=02 type=lead -->
<td align="right" width="1%"></td> <!-- colindex=02 type=body -->
<td align="left" width="4%"></td> <!-- colindex=02 type=hang1 -->
</tr>
<tr align="center" style="font-size: 8pt" valign="bottom">
<td align="center" nowrap="" valign="bottom">

</td>
<td>

</td>
<td align="center" colspan="3" nowrap="" valign="bottom">
<b>(in millions)</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td>
</td>
</tr>
<tr style="background: #CCEEFF" valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<font style="font-size: 10pt">Fair value of Allergan shares
    issued
    </font>
</div>
</td>
<td>

</td>
<td align="right" nowrap="" valign="bottom">
    $
</td>
<td align="right" nowrap="" valign="bottom">
    1,859.3
</td>
<td align="left" nowrap="" valign="bottom">

</td>
</tr>
<tr valign="bottom">
<td align="left" nowrap="" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<font style="font-size: 10pt">Cash consideration
    </font>
</div>
</td>
<td>

</td>
<td align="right" nowrap="" valign="bottom">

</td>
<td align="right" nowrap="" valign="bottom">
    1,409.3
</td>
<td align="left" nowrap="" valign="bottom">

</td>
</tr>
<tr style="background: #CCEEFF" valign="bottom">
<td align="left" nowrap="" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<font style="font-size: 10pt">Transaction costs
    </font>
</div>
</td>
<td>

</td>
<td align="right" nowrap="" valign="bottom">

</td>
<td align="right" nowrap="" valign="bottom">
    22.1
</td>
<td align="left" nowrap="" valign="bottom">

</td>
</tr>
<tr style="font-size: 1pt" valign="bottom">
<td>

</td>
<td>

</td>
<td>

</td>
<td style="border-top: 1px solid #000000">

</td>
<td>

</td>
</tr>
<tr valign="bottom">
<td align="left" nowrap="" valign="bottom">

</td>
<td>

</td>
<td align="right" nowrap="" valign="bottom">
    $
</td>
<td align="right" nowrap="" valign="bottom">
    3,290.7
</td>
<td align="left" nowrap="" valign="bottom">

</td>
</tr>
<tr style="font-size: 1pt" valign="bottom">
<td>

</td>
<td>

</td>
<td>

</td>
<td style="border-top: 3px double #000000">

</td>
<td>

</td>
</tr>
</table><tr style="font-size: 1pt" valign="bottom">
<td width="89%"></td> <!-- colindex=01 type=maindata -->
<td width="2%"></td> <!-- colindex=02 type=gutter -->
<td align="right" width="4%"></td> <!-- colindex=02 type=lead -->
<td align="right" width="1%"></td> <!-- colindex=02 type=body -->
<td align="left" width="4%"></td> <!-- colindex=02 type=hang1 -->
</tr><td width="89%"></td><tr align="center" style="font-size: 8pt" valign="bottom">
<td align="center" nowrap="" valign="bottom">

</td>
<td>

</td>
<td align="center" colspan="3" nowrap="" valign="bottom">
<b>(in millions)</b>
</td>
</tr><td align="center" nowrap="" valign="bottom">

</td><td align="center" colspan="3" nowrap="" valign="bottom">
<b>(in millions)</b>
</td><b>(in millions)</b><tr style="line-height: 3pt; font-size: 1pt">
<td>
</td>
</tr><td>
</td><tr style="background: #CCEEFF" valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<font style="font-size: 10pt">Fair value of Allergan shares
    issued
    </font>
</div>
</td>
<td>

</td>
<td align="right" nowrap="" valign="bottom">
    $
</td>
<td align="right" nowrap="" valign="bottom">
    1,859.3
</td>
<td align="left" nowrap="" valign="bottom">

</td>
</tr><td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<font style="font-size: 10pt">Fair value of Allergan shares
    issued
    </font>
</div>
</td><div style="text-indent: -10pt; margin-left: 10pt">
<font style="font-size: 10pt">Fair value of Allergan shares
    issued
    </font>
</div><font style="font-size: 10pt">Fair value of Allergan shares
    issued
    </font><td>

</td><td align="right" nowrap="" valign="bottom">
    $
</td><td align="right" nowrap="" valign="bottom">
    1,859.3
</td><td align="left" nowrap="" valign="bottom">

</td><tr valign="bottom">
<td align="left" nowrap="" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<font style="font-size: 10pt">Cash consideration
    </font>
</div>
</td>
<td>

</td>
<td align="right" nowrap="" valign="bottom">

</td>
<td align="right" nowrap="" valign="bottom">
    1,409.3
</td>
<td align="left" nowrap="" valign="bottom">

</td>
</tr><td align="left" nowrap="" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<font style="font-size: 10pt">Cash consideration
    </font>
</div>
</td><div style="text-indent: -10pt; margin-left: 10pt">
<font style="font-size: 10pt">Cash consideration
    </font>
</div><font style="font-size: 10pt">Cash consideration
    </font><td>

</td><td align="right" nowrap="" valign="bottom">
    1,409.3
</td><td align="left" nowrap="" valign="bottom">

</td><tr style="background: #CCEEFF" valign="bottom">
<td align="left" nowrap="" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<font style="font-size: 10pt">Transaction costs
    </font>
</div>
</td>
<td>

</td>
<td align="right" nowrap="" valign="bottom">

</td>
<td align="right" nowrap="" valign="bottom">
    22.1
</td>
<td align="left" nowrap="" valign="bottom">

</td>
</tr><td align="left" nowrap="" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<font style="font-size: 10pt">Transaction costs
    </font>
</div>
</td><div style="text-indent: -10pt; margin-left: 10pt">
<font style="font-size: 10pt">Transaction costs
    </font>
</div><font style="font-size: 10pt">Transaction costs
    </font><td>

</td><td align="right" nowrap="" valign="bottom">
    22.1
</td><td align="left" nowrap="" valign="bottom">

</td><tr style="font-size: 1pt" valign="bottom">
<td>

</td>
<td>

</td>
<td>

</td>
<td style="border-top: 1px solid #000000">

</td>
<td>

</td>
</tr><td>

</td><tr valign="bottom">
<td align="left" nowrap="" valign="bottom">

</td>
<td>

</td>
<td align="right" nowrap="" valign="bottom">
    $
</td>
<td align="right" nowrap="" valign="bottom">
    3,290.7
</td>
<td align="left" nowrap="" valign="bottom">

</td>
</tr><td align="left" nowrap="" valign="bottom">

</td><td align="right" nowrap="" valign="bottom">
    $
</td><td align="right" nowrap="" valign="bottom">
    3,290.7
</td><td align="left" nowrap="" valign="bottom">

</td><tr style="font-size: 1pt" valign="bottom">
<td>

</td>
<td>

</td>
<td>

</td>
<td style="border-top: 3px double #000000">

</td>
<td>

</td>
</tr><td>

</td><div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
</div><div style="margin-top: 6pt; font-size: 1pt"></div><div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The value of the shares of Company common stock used in
    determining the purchase price was $106.60per share, based
    on the closing price of the Companys common stock on
    December20, 2005, the effective date of the merger
    agreement.
</div><p align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<br/>
    F-15
</p><br/><p>
</p><h5 align="left" style="page-break-before:always"></h5><p>
</p><div style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->
<div style="margin-top: 18pt; font-size: 1pt"></div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
<b><font style="font-family: 'Times New Roman', Times">ALLERGAN,
    INC.<br/>
</font></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"></div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
<b><font style="font-family: 'Times New Roman', Times">NOTESTO
    CONSOLIDATED FINANCIAL
    STATEMENTS(Continued)</font></b>
</div>
<p>
</p><div style="margin-top: 12pt; font-size: 1pt"></div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
<b><i><font style="font-family: 'Times New Roman', Times">Purchase
    Price Allocation</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"></div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Inamed purchase price was allocated to tangible and
    intangible assets acquired and liabilities assumed based on
    their estimated fair values at the acquisition date
    (March23, 2006). The excess of the purchase price over the
    fair value of net assets acquired was allocated to goodwill. The
    goodwill acquired in the Inamed acquisition is not deductible
    for tax purposes.
</div>
<div style="margin-top: 6pt; font-size: 1pt"></div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Company believes the fair values assigned to the assets
    acquired and liabilities assumed were based on reasonable
    assumptions. The following table summarizes the estimated fair
    values of net assets acquired:
</div>
<div style="margin-top: 6pt; font-size: 1pt"></div>
<table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF" width="100%">
<!-- Table Width Row -->
<tr style="font-size: 1pt" valign="bottom">
<td width="89%"></td> <!-- colindex=01 type=maindata -->
<td width="2%"></td> <!-- colindex=02 type=gutter -->
<td align="right" width="4%"></td> <!-- colindex=02 type=lead -->
<td align="right" width="1%"></td> <!-- colindex=02 type=body -->
<td align="left" width="4%"></td> <!-- colindex=02 type=hang1 -->
</tr>
<tr align="center" style="font-size: 8pt" valign="bottom">
<td align="center" nowrap="" valign="bottom">

</td>
<td>

</td>
<td align="center" colspan="3" nowrap="" valign="bottom">
<b>(in millions)</b>
</td>
</tr>
<tr style="line-height: 3pt; font-size: 1pt">
<td>
</td>
</tr>
<tr style="background: #CCEEFF" valign="bottom">
<td align="left" nowrap="" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<font style="font-size: 10pt">Current assets
    </font>
</div>
</td>
<td>

</td>
<td align="right" nowrap="" valign="bottom">
    $
</td>
<td align="right" nowrap="" valign="bottom">
    323.7
</td>
<td align="left" nowrap="" valign="bottom">

</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<font style="font-size: 10pt">Property, plant and equipment
    </font>
</div>
</td>
<td>

</td>
<td align="right" nowrap="" valign="bottom">

</td>
<td align="right" nowrap="" valign="bottom">
    57.7
</td>
<td align="left" nowrap="" valign="bottom">

</td>
</tr>
<tr style="background: #CCEEFF" valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<font style="font-size: 10pt">Identifiable intangible assets
    </font>
</div>
</td>
<td>

</td>
<td align="right" nowrap="" valign="bottom">

</td>
<td align="right" nowrap="" valign="bottom">
    971.9
</td>
<td align="left" nowrap="" valign="bottom">

</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<font style="font-size: 10pt">In-process research and development
    </font>
</div>
</td>
<td>

</td>
<td align="right" nowrap="" valign="bottom">

</td>
<td align="right" nowrap="" valign="bottom">
    579.3
</td>
<td align="left" nowrap="" valign="bottom">

</td>
</tr>
<tr style="background: #CCEEFF" valign="bottom">
<td align="left" nowrap="" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<font style="font-size: 10pt">Goodwill
    </font>
</div>
</td>
<td>

</td>
<td align="right" nowrap="" valign="bottom">

</td>
<td align="right" nowrap="" valign="bottom">
    1,824.2
</td>
<td align="left" nowrap="" valign="bottom">

</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<font style="font-size: 10pt">Other non-current assets,
    primarily deferred tax assets
    </font>
</div>
</td>
<td>

</td>
<td align="right" nowrap="" valign="bottom">

</td>
<td align="right" nowrap="" valign="bottom">
    56.6
</td>
<td align="left" nowrap="" valign="bottom">

</td>
</tr>
<tr style="background: #CCEEFF" valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<font style="font-size: 10pt">Accounts payable and accrued
    liabilities(a)
    </font>
</div>
</td>
<td>

</td>
<td align="right" nowrap="" valign="bottom">

</td>
<td align="right" nowrap="" valign="bottom">
    (127.0
</td>
<td align="left" nowrap="" valign="bottom">
    )
</td>
</tr>
<tr valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<font style="font-size: 10pt">Deferred tax
    liabilities current and non-current
    </font>
</div>
</td>
<td>

</td>
<td align="right" nowrap="" valign="bottom">

</td>
<td align="right" nowrap="" valign="bottom">
    (362.3
</td>
<td align="left" nowrap="" valign="bottom">
    )
</td>
</tr>
<tr style="background: #CCEEFF" valign="bottom">
<td align="left" valign="bottom">
<div style="text-indent: -10pt; margin-left: 10pt">
<font style="font-size: 10pt">Other non-current liabilities
    </font>
</div>
</td>
<td>

</td>
<td align="right" nowrap="" valign="bottom">

</td>
<td align="right" nowrap="" valign="bottom">
    (33.4
</td>
<td align="left" nowrap="" valign="bottom">
    )
</td>
</tr>
<tr style="font-size: 1pt" valign="bottom">
<td>

</td>
<td>

</td>
<td>

</td>
<td style="border-top: 1px solid #000000">

</td>
<td>

</td>
</tr>
<tr valign="bottom">
<td align="left" nowrap="" valign="bottom">

</td>
<td>

</td>
<td align="right" nowrap="" valign="bottom">
    $
</td>
<td align="right" nowrap="" valign="bottom">
    3,290.7
</td>
<td align="left" nowrap="" valign="bottom">

</td>
</tr>
<tr style="font-size: 1pt" valign="bottom">
<td>

</td>
<td>

</td>
<td>

</td>
<td style="border-top: 3px double #000000">

</td>
<td>

</td>
</tr>
</table>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
</div>
<div style="margin-top: 6pt; font-size: 1pt"></div>
<div style="font-size: 1pt; margin-left: 0%; width: 13%; align: left; border-bottom: 1pt solid #000000"></div><!-- callerid=999 iwidth=455 length=60 -->
<div style="margin-top: 3pt; font-size: 1pt"></div>
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF" width="100%">
<tr>
<td width="4%"></td>
<td width="1%"></td>
<td width="95%"></td>
</tr>
<tr>
<td valign="top">
    (a) </td>
<td></td>
<td valign="bottom">
    Accounts payable and accrued liabilities include approximately
    $10.3million of recognized liabilities related to the
    involuntary termination and relocation of certain Inamed
    employees in accordance with the Emerging Issues Task Force
    (EITF) in EITF Issue
    <font style="white-space: nowrap">No.95-3,</font>
<i>Recognition of Liabilities in Connection with a Purchase
    Business Combination.</i></td>
</tr>
</table>
<div style="margin-top: 6pt; font-size: 1pt"></div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Companys fair value estimates for the purchase price
    allocation may change during the allowable allocation period,
    which is up to one year from the acquisition date, if additional
    information becomes available.
</div>
<div style="margin-top: 12pt; font-size: 1pt"></div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
<b><i><font style="font-family: 'Times New Roman', Times">In-process
    Research and Development</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"></div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In conjunction with the Inamed acquisition, the Company recorded
    a charge to in-process research and development expense of
    $579.3million for acquired in-process research and
    development assets that the Company determined were not yet
    complete and had no alternative future uses in their current
    state.
</div>
<div style="margin-top: 6pt; font-size: 1pt"></div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    These in-process research and development assets are composed of
    Inameds silicone breast implant technology for use in the
    United States, Inameds
    <i>Juvderm</i><sup style="font-size: 85%; vertical-align: text-top"><font style="font-variant: SMALL-CAPS">tm</font></sup>
    dermal filler technology for use in the United States, and
    Inameds
    <i>BIB</i><sup style="font-size: 85%; vertical-align: text-top"><font style="font-variant: SMALL-CAPS">tm</font></sup><font style="font-variant: SMALL-CAPS">
</font><i>BioEnterics</i><sup style="font-size: 85%; vertical-align: text-top"></sup>
    Intragastric Balloon
    (<i>BIB</i><sup style="font-size: 85%; vertical-align: text-top"><font style="font-variant: SMALL-CAPS">tm</font></sup><font style="font-variant: SMALL-CAPS">
</font>System) technology for use in the United States, which
    were valued at $405.8million, $41.2million and
    $132.3million, respectively. All of these assets had not
    received approval by the U.S.Food and Drug Administration
    (FDA) as of the Inamed acquisition date of March23, 2006.
    Because the in-process research and development assets had no
    alternative future use, they were charged to expense on the
    Inamed acquisition date.
</div>
<div style="margin-top: 6pt; font-size: 1pt"></div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As of the Inamed acquisition date, the responsive gel round
    implants were expected to be approved by the FDA in mid-2006 and
    the Style410 was estimated to be approved approximately
    six to twelve months thereafter. The Companys management
    estimated that the projects were approximately 90percent
    complete as the patient data had been collected and submitted to
    the FDA, with remaining efforts focused on responding to FDA
    questions and compiling additional data regarding clinical
    trials and other information necessary to answer any additional
    FDA requests. Subsequently, on November17, 2006, the
    responsive gel round model of the silicone breast implants
    received FDA approval. The Company is required, as a condition
    of approval, to conduct extensive sets of ongoing
</div>
<p align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<br/>
    F-16
</p></div>